Company: BNRG
Filing Date: 2025-11-25
Form Type: 424B3
Source: 0001213900-25-114795
Chunk: 16

Company: Brenmiller Energy Ltd.
Filing Date: 2025-11-25
Form: 424B3
Chunk 16
---
 All net proceeds from the sale of the Ordinary Shares covered by this
prospectus will go to the selling shareholder. However, we will receive cash proceeds equal to conversion price of any Preferred Shares
that are converted to Ordinary Shares and the exercise price of the Warrants that are exercised.

We intend to use the proceeds
from the conversion of any Preferred Shares and exercise of the Warrants for general corporate purposes, working capital, and execution
of our commercial TES projects across Europe, the U.S., and the Middle East.

<div align='center'>9

capitalization</div>

The following table sets
forth our cash and cash equivalents and our capitalization as of June 30, 2025:

| ● | on an actual basis; |

| ● | on a pro forma basis which gives effect to: |

| (i) | the issuance and sale of 476,323                                                      
 Ordinary Shares from July 1, 2025 to the date of this prospectus pursuant to an “at   
 the market offering” program and the receipt, of net proceeds of $1,124 thousand from 
 such sales;                                                                           |

| (ii) | the issuance of an aggregate                                                               
 of 24,850 Ordinary Shares with respect to 24,850 restricted share units we have granted to 
 service providers from July 1, 2025 to the date of this prospectus; and                    |

| (iii) | the issuance of 631,579 ordinary                                                           
 shares with respect to exercise of 631,579 Pre-Funded Warrants and sale of 3,800 Preferred 
 Shares and 2,292,418 warrants pursuant to the July 2025 Securities Purchase Agreement; and |

| ● | on a pro forma as                                                                                                                 
 adjusted basis to give effect to (i) to give effect to the full conversion of Preferred Shares at the conversion price of $2.288, 
 and (ii) the full exercise of the Ordinary Warrants at an exercise price of $2.40 per share.                                      |

The following table should
be read in conjunction with “Use of Proceeds,” our Condensed Consolidated Financial Statements as of and for the Six-Month
Period Ended June 30, 2025 and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
attached as exhibits 99.2 and 99.3, respectively, to our Report of Foreign Private Issuer on Form 6-K, filed with the SEC on September
30, 2025 that